REG - Genflow Biosciences - Receipt of First Tranche of Grant

Genflow BiosciencesAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260302:nRSB8207Ua&default-theme=true

RNS Number : 8207U  Genflow Biosciences PLC  02 March 2026

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Genflow Biosciences Plc

 

Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia
Region for GF-1002 Development

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"),
a leading European-based biotechnology company focusing on longevity, is
pleased to confirm receipt of the first instalment of €336,467 of the
previously announced €4 million non-dilutive grant awarded by the Wallonia
Region of Belgium, (see RNS dated 22 October, 2024 here
(https://www.londonstockexchange.com/news-article/GENF/genflow-secures-non-dilutive-financial-support/16725188)
.)

 

The support package spans a three-year development programme and is aligned
with Genflow's existing roadmap for GF-1002 in MASH.

 

The grant will support the continued development of the Company's lead gene
therapy candidate, GF-1002, with further instalments expected to be received
in accordance with the agreed milestone and disbursement schedule. The first
instalment has been received and will be applied toward eligible
project-related activities.

 

Dr. Eric Leire, CEO of Genflow, commented: "We are pleased to confirm receipt
of the first instalment under the €4 million Wallonia Region grant. This
initial funding supports the continued advancement of GF-1002 in MASH and
strengthens our ability to execute against planned development milestones. We
look forward to progressing the programme and receiving subsequent instalments
in line with the agreed framework."

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, delivers a proprietary
centenarian variant of the SIRT6 gene. The therapy is currently being
evaluated in the Company's randomised, blinded SLAB (Sarcopenia and Longevity
in Aged Beagles) study in dogs aged over 10 years, which commenced in March
2025. Preliminary interim results demonstrated improved survival versus
control during the dosing period, alongside favourable safety and tolerability
and positive trends across functional endpoints including muscle mass
preservation, frailty reduction and quality of life. Other programs include a
clinical trial that will explore the potential benefits of GF-1002 in treating
MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent
chronic liver disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKDBQOBKDFNK



            Copyright 2019 Regulatory News Service, all rights reserved